ProKidney Corp.
Kathleen Conde currently serves as the Executive Assistant to the Chief Executive Officer at ProKidney Corp. since September 2023. Prior to this role, Kathleen spent over a decade at CVS Health, functioning as a C-Suite Executive Assistant from March 2013 to October 2023. Kathleen's extensive experience in administrative support also includes a position as an Executive Assistant at Verizon from December 2011 to March 2013, and a long tenure at Verizon from March 1981 to April 2011 as a Senior Staff Analyst. In this analyst role, Kathleen focused on analyzing technician productivity and collaborated with teams to identify and eliminate roadblocks related to copper installation, maintenance, and FiOS deployment. Education includes various qualifications.
This person is not in any teams
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.